Publications

Safety and Immunogenicity of a Two-Dose AD26.ZEBOV, MVA-BN-FILO EBOLA Vaccine Regimen in Infants: A Randomised, Double-Blind, Controlled Trial in Sierra Leone and Guinea. (Abstract, Presentation ref ID951).

CHOI, E; Baiden, F; AFOLABI, M; Foster, J; MANNO, D; Ishola, D; Njie, Y; Lowe, B; Lawal, B; Otieno, GT; GREENWOOD, B; WATSON-JONES, D;

2022

(2022).

Adding to the mantra: vaccines prevent illness and death, and preserve existing antibiotics.

HEYMANN, DL; Kieny, M-P; Laxminarayan, R;

2022

The Lancet. Infectious diseases, (2022).22 8 10.1016/s1473-3099(22)00374-7.

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.

Feikin, DR; Higdon, MM; Abu-Raddad, LJ; Andrews, N; Araos, R; Goldberg, Y; Groome, MJ; Huppert, A; O'Brien, KL; SMITH, PG; WILDER-SMITH, A; Zeger, S; Deloria Knoll, M; Patel, MK;

2022

Lancet, (2022).399 10328 10.1016/S0140-6736(22)00152-0.

Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.

Burger, EA; Laprise, J-F; Sy, S; Regan, MC; Prem, K; JIT, M; Brisson, M; Kim, JJ;

2022

International Journal of Cancer, (2022).151 10 10.1002/ijc.34054.

Childhood COVID-19 vaccine acceptance and preference from caregivers and healthcare workers in China: A survey experiment.

Hou, Z; Song, K; Wang, Q; Zang, S; Tu, S; CHANTLER, T; LARSON, HJ;

2022

Preventive medicine, (2022).161, 10.1016/j.ypmed.2022.107138.

Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.

Weerasuriya, CK; Harris, RC; MCQUAID, CF; BOZZANI, F; Ruan, Y; Li, R; Li, T; Rade, K; Rao, R; Ginsberg, AM; Gomez, GB; WHITE, RG;

2022

BMC medicine, (2022).20 1 10.1186/s12916-022-02306-3.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modelling study.

Portnoy, A; CLARK, R; Quaife, M; WEERASURIYA, C; Mukandavire, C; Bakker, R; Deol, A; Malhotra, S; Gebreselassie, N; Zignol, M; Sim, SY; Hutubessy, RC W; Baena, IG; Nishikiori, N; JIT, M; WHITE, R; Menzies, N;

2022

medRxiv (2022). 10.1101/2022.05.04.22274654.

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study.

Paternina-Caicedo, A; JIT, M; Alvis-Guzmán, N; Fernández, JC; Hernández, J; Paz-Wilches, JJ; Rojas-Suarez, J; Dueñas-Castell, C; Alvis-Zakzuk, NJ; Smith, AD; Hoz-Restrepo, FD L;

2022

The Lancet Regional Health Americas, (2022).12, 10.1016/j.lana.2022.100296.

T-Cell Responses after Rotavirus Infection or Vaccination in Children: A Systematic Review.

LABAN, NM; GOODIER, MR; Bosomprah, S; Simuyandi, M; Chisenga, C; Chilyabanyama, ON; Chilengi, R;

2022

VIRUSES-BASEL, (2022).14 3 10.3390/v14030459.

Correction: COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.

PEARSON, CA B; BOZZANI, F; PROCTER, SR; DAVIES, NG; Huda, M; JENSEN, HT; KEOGH-BROWN, M; Khalid, M; SWEENEY, S; Torres-Rueda, S; CHiL COVID-19 Working Group,; CMMID COVID-19 Working Group,; EGGO, RM; VASSALL, A; JIT, M;

2022

PLoS medicine, (2022).19 5 10.1371/journal.pmed.1003990.